MedTrace Logo

A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors

NCT07629258 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-14

No results posted yet for this study

Summary

A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.

Conditions

  • Advanced Tumors

Interventions

DRUG

GW01-200

GW01-200 tablets will be administered orally.

Sponsors & Collaborators

  • Groovy Medicine (Hangzhou) Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-17
Primary Completion
2029-01-31
Completion
2029-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629258 on ClinicalTrials.gov